Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
ONXX [NASD]
Onyx Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.51 Insider Own0.62% Shs Outstand72.74M Perf Week-7.43%
Market Cap6.76B Forward P/E168.93 EPS next Y0.55 Insider Trans9.73% Shs Float72.51M Perf Month-5.08%
Income-165.25M PEG- EPS next Q-0.45 Inst Own- Short Float6.61% Perf Quarter28.33%
Sales435.63M P/S15.51 EPS this Y-342.42% Inst Trans4.93% Short Ratio3.82 Perf Half Y27.15%
Book/sh16.09 P/B5.77 EPS next Y132.00% ROA-10.81% Target Price109.18 Perf Year116.93%
Cash/sh10.05 P/C9.25 EPS next 5Y44.40% ROE-17.03% 52W Range41.26 - 101.57 Perf YTD23.01%
Dividend- P/FCF- EPS past 5Y175.12% ROI-11.63% 52W High-8.22% Beta1.14
Dividend %- Quick Ratio- Sales past 5Y31.98% Gross Margin- 52W Low125.93% ATR3.48
Employees741 Current Ratio8.97 Sales Q/Q101.99% Oper. Margin-57.14% RSI (14)48.43 Volatility3.74% 3.55%
OptionableYes Debt/Eq0.15 EPS Q/Q46.33% Profit Margin-37.93% Rel Volume0.72 Prev Close92.91
ShortableYes LT Debt/Eq0.15 EarningsMay 07 AMC Payout- Avg Volume1.26M Price93.22
Recom1.70 SMA20-1.48% SMA501.30% SMA20014.24% Volume51,809 Change0.33%
08-May-13Reiterated Barclays Overweight $93 → $98
22-Feb-13Reiterated Barclays Overweight $97 → $93
19-Dec-12Initiated UBS Buy $97
26-Oct-12Reiterated Maxim Group Buy $95 → $105
11-Oct-12Resumed Canaccord Genuity Buy $105
23-Jul-12Reiterated Rodman & Renshaw Mkt Outperform $73 → $89
23-Jul-12Reiterated Maxim Group Buy $75 → $92
23-Jul-12Reiterated Deutsche Bank Buy $77 → $110
26-Jun-12Reiterated Deutsche Bank Buy $58 → $77
21-Jun-12Upgrade Brean Murray Hold → Buy $60
21-Jun-12Reiterated Rodman & Renshaw Mkt Outperform $57 → $73
21-Jun-12Initiated Deutsche Bank Buy $58
03-May-12Reiterated Barclays Equal Weight $40 → $44
09-Dec-11Initiated Barclays Capital Equal Weight $51
01-Dec-11Initiated Rodman & Renshaw Mkt Outperform $62
23-Aug-11Initiated Summer Street Research Buy $49
12-Apr-11Initiated Maxim Group Buy $43
08-Dec-10Reiterated Barclays Capital Overweight $35 → $42
08-Oct-10Reiterated Brean Murray Buy $39 → $38
27-Jul-10Reiterated MP Advisors Outperform $30 → $35
21-May-13 08:50PM  Onyx Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AM at Seeking Alpha
05:01PM  Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard at TheStreet
04:01PM  InPlay: Onyx Pharma announces data presentations at the 18th Congress of the European Hematology Association Briefing.com
04:00PM  Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association Marketwired
04:00PM  Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology Association Marketwire
18-May-13 02:30PM  Will ASCO Unlock Big Value in This Cancer Drug Class? at Motley Fool
16-May-13 03:39PM  A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical Companies Wall Street Transcript
15-May-13 06:14PM  InPlay: Onyx Pharma announces data presentations at 49th American Society of Clinical Oncology Annual Meeting Briefing.com
06:00PM  Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting Marketwired
06:00PM  Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual Meeting Marketwire
09:24AM  Aveo Screwed Up but Its Kidney Cancer Drug Is Real at TheStreet
14-May-13 01:04PM  ONYX PHARMACEUTICALS INC Financials EDGAR Online Financials
10:15AM  Wider-than-Expected Loss at ChemoCentryx Zacks
13-May-13 08:52AM  3 Earnings Reports That Caught My Attention Last Week at Motley Fool
12-May-13 02:58PM  These 5 Stocks Saw Trading Price Swings This Past Week Post Earnings at Wall St. Cheat Sheet
10-May-13 04:40PM  Onyx Pharmaceuticals Larger Than S&P 500 Component TripAdvisor at Forbes
09-May-13 03:23PM  Good News for Cubist Pharmaceuticals Zacks
01:48PM  1 Casino, 1 Biotech And 1 Sofware Stock With Recent Intensive Insider Selling at Seeking Alpha
01:01PM  6 strong stocks in an overbought market at MarketWatch
12:35PM  Narrower-than-Expected Loss at ArQule Zacks
08-May-13 04:00PM  Onyx Pharmaceuticals to Present at Upcoming Investor Conferences Marketwired +5.85%
04:00PM  Onyx Pharmaceuticals to Present at Upcoming Investor Conferences Marketwire
01:03PM  Today's Stocks Driving Success For The Health Care Sector at TheStreet
09:37AM  ONYX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
07-May-13 10:20PM  Onyx Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
05:22PM  Onyx Pharmaceuticals Earnings: Heres Why Investors are Buying Shares Now at Wall St. Cheat Sheet
04:02PM  InPlay: Onyx Pharma beats by $0.02, beats on revs Briefing.com
04:00PM  Onyx Pharmaceuticals Reports First Quarter 2013 Financial Results Marketwired
04:00PM  Onyx Pharmaceuticals Reports First Quarter 2013 Financial Results Marketwire
12:00PM  Wider-than-Expected Loss at Corcept Zacks
09:15AM  ONYX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
08:45AM  Valeant Misses Earnings and Revenue Estimate in 1Q (Revised) Zacks
07:07AM  Q1 2013 Onyx Pharmaceuticals Earnings Release - After Market Close CCBN
06-May-13 04:00PM  Positive Opinion on Allergan Candidate Zacks
03:00PM  Perrigo Likely to Report In Line Earnings Zacks
12:55PM  Narrower-than-Expected Loss at Cadence Zacks
10:00AM  Onyx Pharmaceuticals Inc. Stock Hold Recommendation Reiterated (ONXX) at TheStreet
05-May-13 04:00PM  Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players at Motley Fool
03-May-13 05:01PM  Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Health Care Laggard at TheStreet
02:35PM  Questcor Misses on Earnings, Revs Zacks
01:25PM  Valeant Beats Earnings, Misses Revs Zacks
01:15PM  Shire Beats Earnings in 1Q Zacks
11:43AM  Drug Manufacturers and the FDA Collaborate More Closely for Faster Drug Approval: An Exclusive Interview with an Expert Equity Analyst Reveals Some Top Stock Picks in This Vital Industry Wall Street Transcript
02-May-13 07:14PM  An FDA Advisory Committee Kill Shot at Motley Fool
05:43PM  Aveo plunges as FDA recommends against cancer drug AP
04:18PM  Why AVEO Pharmaceuticals Shares Were Eviscerated at Motley Fool
01:30PM  ViroPharma Reports Loss in 1Q Zacks
01:05PM  Aveo Fails to Win FDA Panel Backing for Kidney Cancer Drug at Bloomberg
01-May-13 12:25PM  Allergan Beats on Earnings Zacks
11:00AM  Invest In The War On Cancer With These Stocks The StreetAuthority Network
11:00AM  Invest In The War On Cancer With These Stocks
11:00AM  Fight Cancer, Save Lives With These Stocks The StreetAuthority Network
10:05AM  Positive CHMP Opinion for Avanir Zacks
30-Apr-13 09:17PM  The FDA Firing Squad Takes Aim at Motley Fool
01:05PM  Wider Loss at Auxilium, Acquires Actient Zacks
12:44PM  Why AVEO Pharmaceuticals Shares Imploded at Motley Fool
11:31AM  Finding Value in Biotech Pipelines: An Expert Analyst Discusses the Disconnect in the Biotech Sector in How Companies are Valued Relative to What They Can Do Wall Street Transcript
11:07AM  Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks at TheStreet
10:22AM  RPT-UPDATE 1-FDA staff to ask expert panel if new trial needed for Aveo drug at Reuters
10:08AM  UPDATE 1-FDA staff to ask expert panel if new trial needed for Aveo drug at Reuters
09:20AM  FDA staff to ask expert panel if new trial needed for Aveo drug at Reuters
09:12AM  Aveo Kidney Cancer Drug May Need More Study, FDA Says at Bloomberg
09:10AM  Should Aveo Run Second Study of Kidney Cancer Drug, FDA Asks at TheStreet
29-Apr-13 04:00PM  Tackling Cancer: Thyroid Cancer's Biggest Current and Upcoming Players at Motley Fool
12:36PM  An Oncology Stock to Watch at Motley Fool
28-Apr-13 11:45AM  2 FDA Decisions You Can't Afford to Miss This Week at Motley Fool
26-Apr-13 11:50AM  Wall Street Transcript Interview with William A. Hartman, President & Chief Executive Officer of Premier Biomedical, Inc. (BIEI) Wall Street Transcript
25-Apr-13 10:30AM  UCB Sales Drop in 1Q Zacks
10:10AM  Aveo's Kidney Cancer Drug Won't Get FDA Panel OK at TheStreet
06:00AM  Why Aveo's Kidney Cancer Drug Will Be Turned Down By Next Week's FDA Panel at TheStreet
02:21AM  ONYX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
24-Apr-13 10:08AM  Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval at Seeking Alpha
08:40AM  Lilly Earnings Better Than Expected Zacks
22-Apr-13 11:13AM  Onyx Reaches New 52-Week High (ONXX) at TheStreet
18-Apr-13 05:02PM  Healthcare-Focused Hedgie Bullish on These Stocks at Motley Fool
16-Apr-13 04:00PM  Onyx Pharmaceuticals to Report First Quarter 2013 Financial Results After Market on May 7, 2013 Marketwired
04:00PM  Onyx Pharmaceuticals to Report First Quarter 2013 Financial Results After Market on May 7, 2013 Marketwire
15-Apr-13 04:00PM  Will JNJ Miss on Earnings? Zacks
09:06AM  CR Bard Director Sells 100K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
14-Apr-13 12:28PM  2 Biotechs And A Grocery Store With Recent Intensive Insider Selling at Seeking Alpha
12-Apr-13 09:06AM  MetroPCS Vice Chairman Sells 45K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
11-Apr-13 04:00PM  Biopharma CEO: You Really Get It When Youre Treating Your Own Son Off the Cuff
03:30PM  FDA Designation for Pfizer Candidate Zacks
03:20PM  Six stocks to watch for some upside at MarketWatch
03:20PM  Six stocks to watch for some upside at MarketWatch
10-Apr-13 05:50PM  Array Presents ARRY-520 Data Zacks
10:24AM  Onyx Reaches New 52-Week High (ONXX) at TheStreet
08-Apr-13 12:10PM  3 Breakout Stock Plays to Watch at TheStreet
12:03PM  3 Breakout Stock Plays to Watch at TheStreet
05-Apr-13 08:51AM  Paychex Director Sells 10K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
06:00AM  Cramer's Top Stock Picks: QQQ IMGN SGEN ONXX at TheStreet
04-Apr-13 08:21PM  Cramer's 'Mad Money' Recap: Economists Don't Know Stocks at TheStreet
06:25PM  [video] Cramer Talks Biotech Boom at CNBC
05:01PM  Onyx Pharmaceuticals Inc. (ONXX): Drugs' Highlighted Dud Of The Day at TheStreet
03-Apr-13 05:50PM  Celgene's Rich Pipeline Offers Growth at Seeking Alpha
01-Apr-13 04:19PM  Three Outside the Box Biotechs at Motley Fool
03:25PM  8 Stocks Surging on Big Volume at TheStreet
08:32AM  InPlay: Onyx Pharma Pharma announces proteasome inhibitor data presentations at 14th international myeloma workshop; data on Carfilzomib and Oprozomib to Be Presen Briefing.com
08:30AM  Onyx Pharmaceuticals Announces Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop Marketwired
08:30AM  Onyx Pharmaceuticals Announces Proteasome Inhibitor Data Presentations at 14th International Myeloma Workshop Marketwire
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals Inc., develops and markets Nexavar tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer; and Stivarga tablets to treat metastatic colorectal cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of liver, kidney, thyroid, breast, and non-small cell lung cancers; and completed Phase III clinical trials on Stivarga to treat gastro intestinal stromal tumor. In addition, the company is developing Kyprolis, a proteasome inhibitor in Phase III and Phase I/II clinical trials to treat multiple myeloma; Phase II clinical trials to treat solid tumor; and Phase I clinical trials to treat hematologic malignancies, as well as provides research and development services to Palbociclib, a cell cycle kinase inhibitor in Phase II clinical trials to restore control in the misregulated cell cycle in tumor cells. Further, it offers Oprozomib, an oral proteasome inhibitor in Phase Ib/II clinical trials to treat patients with hematologic malignancies; ONX 0914, an inhibitor of the immunoproteasome in preclinical stage; and ONX 0801, a novel targeted oncology compound in Phase I clinical trials to combine two proven approaches to improve outcomes for cancer patients. Onyx Pharmaceuticals, Inc. was founded in 1992 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lasowski JuergenEVP, Corp. Dev & StrategyMay 14Sale96.604,182403,96732,083May 16 08:39 PM
Fust Matthew KEVP & Chief Financial OfficerMay 13Option Exercise34.4810,269354,07560,473May 15 06:51 PM
Torley HelenEVP, Chief Commercial OfficerMay 13Option Exercise34.308,250283,00055,896May 15 07:43 PM
Fust Matthew KEVP & Chief Financial OfficerMay 13Sale98.2210,2691,008,59850,204May 15 06:51 PM
Torley HelenEVP, Chief Commercial OfficerMay 13Sale98.138,250809,61047,646May 15 07:43 PM
GODDARD PAULDirectorMay 08Option Exercise28.411,00028,41015,890May 08 08:43 PM
GODDARD PAULDirectorMay 08Sale95.001,00095,00014,890May 08 08:43 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryMay 07Option Exercise34.304,051138,96638,669May 08 08:43 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesMay 07Option Exercise31.158,877276,54835,943May 08 08:44 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryMay 07Sale89.974,051364,48434,618May 08 08:43 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesMay 07Sale89.848,877797,49627,066May 08 08:44 PM
WIGGANS THOMAS GDirectorMay 06Option Exercise26.344,500118,51013,465May 08 08:43 PM
WIGGANS THOMAS GDirectorMay 06Sale91.014,500409,5458,965May 08 08:43 PM
GODDARD PAULDirectorMay 01Option Exercise15.685,00078,41019,890May 03 04:37 PM
GODDARD PAULDirectorMay 01Sale93.025,000465,08714,890May 03 04:37 PM
GRILLO LOPEZ ANTONIO JDirectorApr 23Option Exercise37.685,000188,40011,600Apr 24 04:11 PM
GRILLO LOPEZ ANTONIO JDirectorApr 23Sale101.285,000506,4006,600Apr 24 04:11 PM
Fust Matthew KEVP & Chief Financial OfficerApr 15Sale95.151,347128,16750,204Apr 16 04:23 PM
GRILLO LOPEZ ANTONIO JDirectorApr 11Option Exercise29.2443,1641,261,93236,600Apr 11 09:47 PM
LUNDBERG MAGNUSDirectorApr 11Option Exercise16.2810,000162,80024,216Apr 11 09:02 PM
GRILLO LOPEZ ANTONIO JDirectorApr 11Sale96.7343,1644,175,1146,600Apr 11 09:47 PM
LUNDBERG MAGNUSDirectorApr 11Sale96.0010,000960,00014,216Apr 11 09:02 PM
WOOD JULIANNA RVP, Public AffairsApr 10Option Exercise33.989,948338,07225,992Apr 11 09:45 PM
GODDARD PAULDirectorApr 10Option Exercise28.412,00056,82016,890Apr 11 08:50 PM
WOOD JULIANNA RVP, Public AffairsApr 10Sale95.009,948945,07119,374Apr 11 09:45 PM
GODDARD PAULDirectorApr 10Sale95.002,000190,00014,890Apr 11 08:50 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryApr 08Option Exercise34.314,052139,00736,488Apr 10 06:01 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryApr 08Sale89.184,052361,33834,618Apr 10 06:01 PM
WIGGANS THOMAS GDirectorApr 05Option Exercise25.302,50063,25012,665Apr 09 06:36 PM
WIGGANS THOMAS GDirectorApr 05Sale86.003,700318,2008,965Apr 09 06:36 PM
COLES N ANTHONYChairman & CEOApr 03Option Exercise28.9317,278499,899131,198Apr 03 08:20 PM
COLES N ANTHONYChairman & CEOApr 03Sale89.509,705868,620113,920Apr 03 08:20 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesApr 02Sale89.621,767158,35927,066Apr 03 07:51 PM
LUNDBERG MAGNUSDirectorApr 01Option Exercise23.7010,000237,00024,216Apr 03 07:52 PM
GRILLO LOPEZ ANTONIO JDirectorApr 01Option Exercise24.1525,000603,75031,600Apr 03 08:20 PM
Lasowski JuergenEVP, Corp. Dev & StrategyApr 01Sale86.142,651228,35036,265Apr 03 07:52 PM
Fust Matthew KEVP & Chief Financial OfficerApr 01Sale86.143,861332,57551,551Apr 03 07:51 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesApr 01Sale86.152,066177,98628,833Apr 03 07:51 PM
WOOD JULIANNA RVP, Public AffairsApr 01Sale86.1590778,13819,374Apr 03 07:50 PM
Torley HelenEVP, Chief Commercial OfficerApr 01Sale86.1446640,14147,646Apr 03 07:50 PM
LUNDBERG MAGNUSDirectorApr 01Sale92.0010,000920,00014,216Apr 03 07:52 PM
COLES N ANTHONYChairman & CEOApr 01Sale86.1411,6291,001,722123,625Apr 03 08:20 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryApr 01Sale88.145,215459,65934,618Apr 03 08:21 PM
GRILLO LOPEZ ANTONIO JDirectorApr 01Sale91.3625,0002,284,0166,600Apr 03 08:20 PM
COLES N ANTHONYChairman & CEOMar 28Option Exercise35.1810,938384,799119,392Apr 01 07:36 PM
COLES N ANTHONYChairman & CEOMar 28Sale90.0010,938984,420108,454Apr 01 07:36 PM
WOOD JULIANNA RVP, Public AffairsMar 11Option Exercise33.323,331110,99021,550Mar 13 07:37 PM
LUNDBERG MAGNUSDirectorMar 11Option Exercise38.855,000194,25017,116Mar 13 07:37 PM
LUNDBERG MAGNUSDirectorMar 11Sale88.005,000440,00012,116Mar 13 07:37 PM
WOOD JULIANNA RVP, Public AffairsMar 11Sale85.653,331285,30018,219Mar 13 07:37 PM
GODDARD PAULDirectorMar 08Option Exercise28.411,00028,41013,790Mar 11 05:49 PM
WIGGANS THOMAS GDirectorMar 08Option Exercise27.632,00055,26010,065Mar 11 05:50 PM
WIGGANS THOMAS GDirectorMar 08Sale85.002,000170,0008,065Mar 11 05:50 PM
GODDARD PAULDirectorMar 08Sale85.001,00085,00012,790Mar 11 05:49 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryMar 07Option Exercise34.304,054139,07237,887Mar 11 05:48 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryMar 07Sale79.724,054323,18533,833Mar 11 05:48 PM
WIGGANS THOMAS GDirectorMar 05Option Exercise25.302,50063,25010,565Mar 05 08:14 PM
Fust Matthew KEVP & Chief Financial OfficerMar 05Option Exercise34.482,21176,23547,412Mar 05 08:14 PM
WIGGANS THOMAS GDirectorMar 05Sale77.202,500193,0008,065Mar 05 08:14 PM
GODDARD PAULDirectorMar 01Option Exercise12.504,00050,00016,790Mar 05 08:13 PM
GODDARD PAULDirectorMar 01Sale74.354,000297,40012,790Mar 05 08:13 PM
Fust Matthew KEVP & Chief Financial OfficerFeb 28Option Exercise34.4810,000344,80060,201Mar 04 06:39 PM
Fust Matthew KEVP & Chief Financial OfficerFeb 28Sale77.1215,0001,156,80045,201Mar 04 06:39 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesFeb 15Option Exercise30.5116,164493,18641,663Feb 20 07:16 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesFeb 15Sale74.9616,1641,211,65325,499Feb 20 07:16 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryFeb 07Option Exercise34.314,051138,97237,884Feb 11 09:30 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryFeb 07Sale77.524,051314,03433,833Feb 11 09:30 PM
WIGGANS THOMAS GDirectorFeb 05Option Exercise25.302,50063,25010,565Feb 06 07:22 PM
WIGGANS THOMAS GDirectorFeb 05Sale77.292,500193,2258,065Feb 06 07:22 PM
Torley HelenEVP, Chief Commercial OfficerFeb 04Option Exercise34.308,250283,00047,762Feb 06 07:22 PM
Torley HelenEVP, Chief Commercial OfficerFeb 04Sale78.618,250648,53339,512Feb 06 07:22 PM
WIERENGA WENDALLDirectorFeb 01Sale77.7125019,4289,080Feb 05 07:04 PM
Fust Matthew KEVP & Chief Financial OfficerJan 10Option Exercise34.487,112245,22260,400Jan 11 08:32 PM
Fust Matthew KEVP & Chief Financial OfficerJan 10Sale84.8710,199865,58250,201Jan 11 08:32 PM
GODDARD PAULDirectorJan 09Option Exercise33.565,000167,80017,790Jan 11 08:30 PM
WOOD JULIANNA RVP, Public AffairsJan 09Option Exercise34.326,622227,24424,841Jan 11 08:31 PM
WOOD JULIANNA RVP, Public AffairsJan 09Sale85.006,622562,87018,219Jan 11 08:31 PM
GODDARD PAULDirectorJan 09Sale83.205,000416,00012,790Jan 11 08:30 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryJan 07Option Exercise35.376,240220,72440,073Jan 09 06:39 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryJan 07Sale81.336,240507,49433,833Jan 09 06:39 PM
GRILLO LOPEZ ANTONIO JDirectorDec 12Sale82.257,265597,5464,500Dec 14 05:59 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryDec 10Option Exercise35.9912,084434,90548,231Dec 12 08:13 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryDec 10Sale77.6814,3981,118,43733,833Dec 12 08:13 PM
Fust Matthew KEVP & Chief Financial OfficerNov 28Option Exercise34.4896633,30853,123Nov 30 07:23 PM
Nevinny Corinne HDirectorNov 28Sale75.003,964297,3007,500Dec 03 05:01 PM
Torley HelenEVP, Chief Commercial OfficerNov 12Option Exercise34.308,250283,00051,509Nov 30 07:23 PM
Torley HelenEVP, Chief Commercial OfficerNov 12Sale75.2211,997902,41439,512Nov 30 07:23 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryNov 07Option Exercise31.482,00162,99638,148Nov 08 07:58 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryNov 07Sale75.142,001150,35536,147Nov 08 07:58 PM
RINGO WILLIAM RDirectorNov 07Sale75.011,30097,5147,737Nov 08 07:57 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesNov 06Option Exercise37.684,775179,92232,611Nov 08 07:56 PM
Foster-Cheek Kaye ISVP, Global Human ResourcesNov 06Sale75.907,112539,80125,499Nov 08 07:56 PM
WIERENGA WENDALLDirectorNov 01Sale77.2125019,3039,330Nov 02 05:47 PM
COLES N ANTHONYPresident & CEOOct 16Option Exercise30.96125,5993,888,295233,942Oct 17 06:27 PM
WOOD JULIANNA RVP, Public AffairsOct 10Option Exercise29.482,85384,10421,072Oct 10 07:00 PM
WOOD JULIANNA RVP, Public AffairsOct 10Sale86.952,853248,06818,219Oct 10 07:00 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryOct 08Option Exercise31.482,00062,96638,147Oct 10 05:22 PM
SHEMA SUZANNE MEVP, GC and Corp. SecretaryOct 08Sale91.012,000182,02036,147Oct 10 05:22 PM
Lasowski JuergenEVP, Corp. Dev & StrategyOct 05Sale90.005,902531,18031,816Oct 05 07:32 PM
Torley HelenEVP, Chief Commercial OfficerOct 04Sale86.512,314200,18443,259Oct 05 04:22 PM
open in yahoo | open in reuters | open in google